[Patient follow-up after treatment of breast, colorectal and prostate cancer].
The prevalence of malignant tumors (not including non-melanoma skin cancer) in the Czech Republic exceeds 350,000 persons, including patients with active disease and those with a history of malignancy. A substantial portion of this population are in long-term complete remission after cancer treatment. These patients are at high risk of cancer recurrence and long-term complications associated with previous cancer therapy. The aim of this review is to summarize current follow-up recommendations for the three most common solid tumor types, including breast, colorectal, and prostate cancer.Key words: breast cancer - colorectal cancer - follow-up - prevalence - prostate cancer.
Tomáš
T
Büchler